Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.

International journal of clinical practice - 1 Jul 2004

Danalioglu A, Kaymakoglu S, Cakaloglu Y, Demir K, Karaca C, Durakoglu Z, Bozaci M, Badur S, Cevikbas U, Okten A

Abstract excerpt

OBJECTIVES: The occurrence of lamivudine resistance is often associated with the clinical breakthrough, which is characterised by the reappearance of hepatitis B virus (HBV) DNA in serum and the elevation of aminotransferases. We evaluated the efficacy of alpha interferon for clinical breakthrough in patients receiving lamivudine therapy. PATIENTS: Six chronic hepatitis B patients receiving lamivudine were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to Drug Therapy, Combination

Share to Hepatitis B, Chronic

Share to Interferon-alpha

Share to Lamivudine

Share to Treatment Outcome

Source

Identifiers

PMID: 15311721
DOI: 10.1111/j.1368-5031.2004.00011.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B.PMID 15311721Read ↗

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.Semantic proximity Read ↗

Subclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine.Semantic proximity Read ↗

[Clinical and virologic characteristics of lamivudine resistance in HBV-associated chronic liver disease].Semantic proximity Read ↗

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.Semantic proximity Read ↗

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].Semantic proximity Read ↗

Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.Semantic proximity Read ↗

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.Semantic proximity Read ↗

Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.Semantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.